Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.9226
Nov 20 • 3:59 PM ET Dollar change-0.0774 Percentage change(-7.74%)
Aftermarket Close
0.9300
Aftermarket • 7:45 PM ET Dollar change+0.0074 Percentage change(0.80%)
Index
-
Market Cap
20.20M
Enterprise Value
-39.58M
Income
-72.76M
Sales
0.00M
Book/sh
2.63
Cash/sh
2.76
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
40
IPO
Feb 13, 2025
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.35
P/C
0.33
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
9.11
Current Ratio
9.11
Debt/Eq
0.01
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-3.33
EPS next Y
-2.40
EPS next Q
-0.78
EPS this Y
-12.63%
EPS next Y
27.15%
EPS next 5Y
8.12%
EPS past 3/5Y
-60.85% -
Sales past 3/5Y
- -
EPS Y/Y TTM
-48.29%
Sales Y/Y TTM
-
EPS Q/Q
-16.83%
Sales Q/Q
-
Insider Own
41.42%
Insider Trans
-0.84%
Inst Own
25.78%
Inst Trans
0.86%
ROA
-73.48%
ROE
-80.85%
ROIC
-125.95%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-26.38%
SMA50
-72.45%
SMA200
-82.77%
Trades
Shs Outstand
21.89M
Shs Float
12.82M
52W High
16.60 -94.44%
52W Low
0.91 1.81%
Volatility
22.97% 24.44%
ATR (14)
0.32
RSI (14)
28.66
Beta
4.28
Rel Volume
0.38
Avg Volume
637.00K
Volume
241,088
Perf Week
-30.63%
Perf Month
-76.64%
Perf Quarter
-86.59%
Perf Half Y
-79.68%
Perf YTD
-92.97%
Perf Year
-90.22%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
1.00
Price
0.92
Change %
-7.74%
Consensus
Hold
Avg. Price Target
$3.50
Implied Upside
+279.4%
Analysts11incl. previous ratings
Rating Distribution6 Buy · 4 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 05, 2026Downgrade
RJF logoRRaymond James
Strong Buy → Mkt Perform
May 15, 2026Downgrade
MS logoMMorgan Stanley
Equal-Weight → Underweight$3+225.2%
Mar 02, 2026Downgrade
SF logoSStifel
Buy → Hold$6+550.3%
Mar 02, 2026Downgrade
RY logoRRBC Capital Mkts
Outperform → Sector Perform$6+550.3%
Mar 02, 2026Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$7+658.7%
Mar 02, 2026Downgrade
HH.C. Wainwright
Buy → Neutral
Jan 28, 2026Initiated
RILY logoRB. Riley Securities
Buy$32+3,368.5%
Dec 23, 2025Initiated
OPY logoOOppenheimer
Outperform$35+3,693.6%
Dec 12, 2025Initiated
WWilliam Blair
Outperform
Dec 03, 2025Initiated
RJF logoRRaymond James
Strong Buy$47+4,994.3%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sun NelsonSee RemarksSep 11 '26Sale5.1862,000321,17935,475Sep 11 08:14 PM
Sun NelsonSee RemarksSep 10 '26Sale5.0014,75473,77997,475Sep 11 08:14 PM
NELSON SUN OfficerSep 11 '26Proposed Sale5.0133,911169,894Sep 11 04:51 PM
NELSON SUN OfficerSep 10 '26Proposed Sale4.9242,843210,788Sep 10 05:18 PM
Sun NelsonChief Financial OfficerDec 11 '25Buy14.403,00043,200108,484Dec 12 08:30 PM
Lee Tien-LiChief Executive OfficerDec 11 '25Buy14.487,000101,3951,551,613Dec 12 08:30 PM
Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
CEODr. Tien-Li Lee M.D.
CFO & COOMr. Nelson B. Sun M.B.A.
M.P.H.Dr. Manasi Sinha Jaiman M.D.
Executive Vice President of Medical AffairsDr. Dvorit Samid Ph.D.
Chief Research OfficerDr. Zhenhuan Zheng Ph.D.